论文检索

Cox 模型中的亚组处理效应一致性检验AI 解读

An overall treatment effect in a clinical trial may inadequately represent particular patient subgroups, creating uncertainty about whether a population-level efficacy conclusion can legitimately be transferred to them. Conventional interaction tests only investigate whether subgroup-specific treatment effects are exactly equal or not, but cannot detect whether the differences are small enough to be clinically negligible. We develop a formal framework for assessing subgroup…

穷尽子组处理效应图中反对同质性的证据评估AI 解读

Exhaustive subgroup treatment effect plots are constructed by displaying all subgroup treatment effects of interest against subgroup sample size, providing a useful overview of the observed treatment effect heterogeneity in a clinical trial. As in any exploratory subgroup analysis, however, the observed estimates suffer from small sample sizes and multiplicity issues. To facilitate more interpretable exploratory assessments, this paper introduces a computationally efficient…

临床试验中的数据驱动子群选择与错误率控制AI 解读

Subgroup selection in clinical trials is essential for identifying patient groups that react differently to a treatment, thereby enabling personalised medicine. In particular, subgroup selection can identify patient groups that respond particularly well to a treatment or that encounter adverse events more often. However, this is a post-selection inference problem, which may pose challenges for traditional techniques used for subgroup analysis, such as increased Type I error…

随机对照试验中协变量调整的使用：综述AI 解读

There has been a growing interest in covariate adjustment in the analysis of randomized controlled trials in past years. For instance, the U.S. Food and Drug Administration recently issued guidance that emphasizes the importance of distinguishing between conditional and marginal treatment effects. Although these effects coincide in linear models, this is not typically the case in other settings, and this distinction is often overlooked in clinical trial practice. Considering…

受新冠疫情影响的临床试验：目标估计量及其估计方法AI 解读

The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as site closures, travel limitations and interruptions to the supply chain for the investigational product, or from health-related challenges such as COVID-19 infections. Some of these complications lead to unforeseen intercurrent events in the sense that they affect either the interpretation or the existence of the…